Evidence map›Paper›PMID 39691506›Full record

ArticleLeukemia research reports2025

Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report.

Grace S Park, Himachandana Atluri, Courtney D DiNardo, Bryan Guillroy, Jean Horak, Effrosyni Apostolidou, Maryam Buni, Guillermo Montalban Bravo, Naveen Pemmaraju

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Grace S ParkDepartment of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Himachandana AtluriDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Bryan GuillroyDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jean HorakDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Effrosyni ApostolidouDepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Maryam BuniDepartment of Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Guillermo Montalban BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delayed hemolytic transfusion reaction (DHTR) poses a significant challenge in patients receiving blood transfusions. This case report highlights the complexities of managing DHTR in a newly diagnosed chronic myelomonocytic leukemia (CMML) patient with clinically significant JKa and little c antibodies during induction chemotherapy. A 46-year-old woman with CMML-2 who presented for induction chemotherapy was found to have hemolytic anemia. Due to presence of JKa and little c antibodies, she required intensive monitoring and supportive care measures. The coexistence of JKa and little c antibodies complicates transfusion management and chemotherapy tolerance in CMML patients.

Indexed as

CMMLHemolytic transfusion reactionsInduction therapy

Identifiers

PMID39691506
PMCPMC11647623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.